| Charlotte Foremaster, | |
|
5983 S Redwood Rd, Taylorsville, UT 84123-5261 | |
| (801) 293-9999 | |
| Not Available |
| Full Name | Charlotte Foremaster |
|---|---|
| Gender | Female |
| Speciality | Licensed Vocational Nurse |
| Location | 5983 S Redwood Rd, Taylorsville, Utah |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316602915 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164X00000X | Licensed Vocational Nurse | 11830813-3101 (Utah) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Charlotte Foremaster, 5983 S Redwood Rd, Taylorsville, UT 84123-5261 Ph: () - | Charlotte Foremaster, 5983 S Redwood Rd, Taylorsville, UT 84123-5261 Ph: (801) 293-9999 |
News Archive
What if it were possible to go to the store and buy a kit to quickly and accurately diagnose cancer, similar to a pregnancy test? A University of Missouri researcher is developing a tiny sensor, known as an acoustic resonant sensor, that is smaller than a human hair and could test bodily fluids for a variety of diseases, including breast and prostate cancers.
A new study finds that these critical access hospitals, which are exempt from reporting certain quality and outcomes data to the federal government, are not matching the gains made by other facilities regarding mortality rates after treatment for heart attacks, heart failure and pneumonia.
A study led by Karolinska Institutet in Sweden reports for the first time the positive effects of an active vaccine against Alzheimer's disease. The new vaccine, CAD106, can prove a breakthrough in the search for a cure for this seriously debilitating dementia disease. The study is published in the distinguished scientific journal Lancet Neurology.
Aeterna Zentaris Inc. a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received a positive opinion for orphan medicinal product designation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for its compound AEZS-108 for the treatment of ovarian cancer. AEZS-108, the Company's doxorubicin targeted conjugate compound, is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in Europe.
There are several effective interventions to reduce the risk of suicide, the tenth-leading cause of death in the United States, but difficulties in identifying people at risk for suicide and concerns about the potentially high costs of suicide-prevention strategies have hampered their wider use.
› Verified 6 days ago